Growth Metrics

BridgeBio Pharma (BBIO) Total Debt (2019 - 2025)

Historic Total Debt for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $740.4 million.

  • BridgeBio Pharma's Total Debt rose 6972.59% to $740.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.4 million, marking a year-over-year increase of 6972.59%. This contributed to the annual value of $738.9 million for FY2024, which is 6550.12% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Total Debt is $740.4 million, which was up 6972.59% from $738.9 million recorded in Q4 2024.
  • In the past 5 years, BridgeBio Pharma's Total Debt registered a high of $740.4 million during Q3 2025, and its lowest value of $94.4 million during Q1 2021.
  • For the 5-year period, BridgeBio Pharma's Total Debt averaged around $411.0 million, with its median value being $434.7 million (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Total Debt skyrocketed by 35982.76% in 2022, and later crashed by 124.51% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Total Debt (Quarter) stood at $430.8 million in 2021, then grew by 0.06% to $431.0 million in 2022, then grew by 3.59% to $446.4 million in 2023, then soared by 65.5% to $738.9 million in 2024, then grew by 0.2% to $740.4 million in 2025.
  • Its Total Debt was $740.4 million in Q3 2025, compared to $738.9 million in Q4 2024 and $436.2 million in Q3 2024.